Joshua Brody, Associate Professor, Division of Hematology and Oncology at Icahn School of Medicine at Mount Sinai, shared on LinkedIn:
“Great quick chat with Dr Urshila Durani on transformative lymphoma immunotherapy trial resulting in FDA approval of combination bispecific antibody therapy.”
More posts about lymphoma.